Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Phase 1 / Phase 2 | terminated | Mar 9, 2022 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT03176277 | A Study of ONO-7475 in Patients With Acute Leukemias | Phase 1 / Phase 2 | terminated | Jun 5, 2017 | Ono Pharmaceutical Co., Ltd. | Protocol defined futility criteria | Efficacy / futility |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Phase 1 / Phase 2 | withdrawn | Jul 7, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual, no participants enrolled | Enrollment / accrual |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT04920188 | Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) | — | terminated | Jun 9, 2021 | UNC Lineberger Comprehensive Cancer Center | Resources related issues | Other (stated, no rule matched) |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic… | Phase 2 | terminated | Apr 18, 2016 | TG Therapeutics, Inc. | (Strategic/Business Decision) | Sponsor / business decision |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed…(HEM-iSMART A) | Phase 1 / Phase 2 | withdrawn | Feb 23, 2023 | Princess Maxima Center for Pediatric Oncology | Company stopped development and production of one of the IMP's. | Sponsor / business decision |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic… | Phase 2 | withdrawn | Mar 29, 2024 | Northside Hospital, Inc. | Unable to accommodate FDA recommendations for protocol revisions | Other (stated, no rule matched) |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients…(PAVE) | Phase 1 | terminated | Nov 21, 2019 | Medical College of Wisconsin | Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no… | Other (stated, no rule matched) |
| NCT04336982 | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid… | Phase 1 | terminated | Apr 7, 2020 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade… | Phase 2 | terminated | Aug 25, 2020 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With…(LAMIPA) | — | withdrawn | Apr 4, 2022 | Centre Hospitalier Régional Metz-Thionville | investigator's unavailability | Investigator |
| NCT03175978 | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome | Phase 1 / Phase 2 | terminated | Jun 5, 2017 | IGF Oncology, LLC | Funding | Funding |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and… | Phase 1 | terminated | Jun 30, 2006 | Kyowa Kirin, Inc. | Terminated due to suboptimal dosing schedule | Other (stated, no rule matched) |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute… | Phase 2 | withdrawn | Jan 18, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With…(AML-ViVA) | Phase 2 | terminated | Oct 24, 2016 | University Hospital Regensburg | Due to financial reasons. | Funding |
| NCT05410574 | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | N/A | terminated | Jun 8, 2022 | Washington University School of Medicine | Insufficient staff | Other (stated, no rule matched) |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic… | Phase 1 | terminated | Jul 4, 2014 | Kyowa Kirin, Inc. | Failed treatment response | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT00779480 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute… | Phase 1 | terminated | Oct 24, 2008 | Kyowa Kirin Co., Ltd. | Failure to demonstrate a tolerable dose that had potential for efficacy. | Efficacy / futility |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid…(AML) | Phase 3 | terminated | Oct 1, 2020 | Jazz Pharmaceuticals | Study enrollment was terminated on 16 May 2022 due to slow recruitment. | Enrollment / accrual |
| NCT06362031 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource… | — | withdrawn | Apr 12, 2024 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS… | Phase 1 / Phase 2 | withdrawn | May 10, 2022 | Novartis Pharmaceuticals | waiting for update from Study Lead | Other (stated, no rule matched) |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT02455024 | An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular…(OMNI) | — | terminated | May 27, 2015 | Ariad Pharmaceuticals | Business Decision; Insufficient Enrollment | Enrollment / accrual |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | Phase 2 | withdrawn | Jul 20, 2022 | Sunnybrook Health Sciences Centre | Funding pulled | Funding |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's… | Phase 3 | withdrawn | Jan 16, 2024 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Business objectives have changed. | Sponsor / business decision |
| NCT02446145 | A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag…(DELTA) | Phase 2 | terminated | May 18, 2015 | Technische Universität Dresden | Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an… | COVID-19 / pandemic |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When… | Phase 1 / Phase 2 | terminated | Oct 3, 2019 | Kartos Therapeutics, Inc. | In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety… | Safety / toxicity |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic… | Phase 1 / Phase 2 | terminated | Mar 11, 2021 | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2… | Safety / toxicity |
| NCT02734823 | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility… | — | withdrawn | Apr 12, 2016 | University of Southern California | Lack of accrual | Enrollment / accrual |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell… | Phase 1 / Phase 2 | withdrawn | Mar 31, 2017 | Zhujiang Hospital | The company did not offer the appropriate CART services. | Sponsor / business decision |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | Phase 1 / Phase 2 | withdrawn | Nov 14, 2022 | Zhujiang Hospital | The company failed to provide corresponding CART services. | Sponsor / business decision |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | Phase 2 | withdrawn | Jun 12, 2019 | Ludwig-Maximilians - University of Munich | Lack of potential study subjects due to a change of standard of care treatment outside of clinical… | Other (stated, no rule matched) |
| NCT04968860 | Oral Health Condition and Quality of Life in Children With Leukemia | — | terminated | Jul 20, 2021 | Paulo Sergio da Silva Santos | Low casuistry that did not allow the study to continue | Other (stated, no rule matched) |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid… | Phase 1 | withdrawn | Feb 9, 2023 | Jonsson Comprehensive Cancer Center | trial was not opened | Other (stated, no rule matched) |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2023 | M.D. Anderson Cancer Center | Zero participants accrued | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT04912063 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used… | Phase 1 | terminated | Jun 3, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05345938 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid… | Phase 1 / Phase 2 | terminated | Apr 26, 2022 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Adjust the research strategy. | Sponsor / business decision |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia… | Phase 2 | withdrawn | Apr 14, 2021 | University of Michigan Rogel Cancer Center | The PI plans to revise the study design in a new protocol | Other (stated, no rule matched) |
| NCT02841540 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes(Encore-MDS) | Phase 1 | terminated | Jul 22, 2016 | Hemavant Sciences GmbH | The study was terminated after conducting an interim analysis of the available data where it became… | Efficacy / futility |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During… | Phase 2 | terminated | Jul 24, 2015 | Weill Medical College of Cornell University | Slow accrual and change in direction of cord blood program | Enrollment / accrual |
| NCT04956042 | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jul 9, 2021 | CicloMed LLC | Discontinued | Other (stated, no rule matched) |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | Phase 2 | withdrawn | Apr 25, 2023 | Uwe Platzbecker | Trial was stopped prematurely due to safety reasons | Safety / toxicity |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic… | Phase 1 / Phase 2 | suspended | Dec 23, 2021 | Cyclacel Pharmaceuticals, Inc. | Slow enrollment and financial limitations | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 18, 2024source: clinicaltrials